COMMUNIQUÉS West-GlobeNewswire

Ibogaine and the Bicameral Mind: The Definitive Clinical and Cultural Guide to Ibogaine Publishes Today
08/09/2026
Ambio Life Sciences CEO Jonathan Dickinson draws on 17 years of clinical practice and Bwiti initiation to bridge tradition and modern neuroscience Foreword by former Texas Governor Rick Perry; praise from Rick Doblin ( [...]
Collegium to Participate in Upcoming Investor Conferences
08/09/2026
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often [...]
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
08/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program
08/09/2026
Company Anticipates $7M-$8M FY’26 Adjusted Gross Profit (1) , vs. Prior Guidance $5M-$7M Company Anticipates Adjusted Net Operating Cash Flow ( 4 ) to Turn Positive in Q3’26 Company Anticipates Generating Positive Core [...]
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
08/09/2026
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
08/09/2026
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, [...]
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
Notice to Convene an Extraordinary General Meeting of Genmab A/S
08/09/2026
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be [...]
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
08/09/2026
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever [...]
MediciNova to Participate in Two Investor Conferences in September
08/09/2026
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
08/09/2026
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
08/09/2026
Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical Officer Expanded leadership team brings decades of [...]
Transactions in connection with share buy-back program
08/09/2026
Company announcement no. 34 - 26 08 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Du massage intelligent au bien-être proactif : SKG élargit sa gamme de dispositifs de santé portables à l’occasion de l’IFA 2026
08/09/2026
La présentation à Berlin associe la technologie de massage portable de SKG à la récupération, à l’accompagnement de l’entraînement et au suivi préventif de la santé BERLIN, 08 sept. 2026 (GLOBE NEWSWIRE) -- SKG Health [...]
From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026
08/09/2026
Berlin showcase connects SKG's portable massage technology with recovery, training support and proactive health monitoring BERLIN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SKG Health is showcasing an expanded portfolio of [...]
New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
08/09/2026
Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple cancer types and [...]
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
08/09/2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled [...]
Rapid Nutrition Reports 227.5% H1 Revenue Growth as Group Enters Transformational Second Half
08/09/2026
Completion of the HealthShop+ acquisition shortly before period-end establishes a materially enlarged operating and revenue base for H2 and beyond LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext [...]
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
08/09/2026
Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence [...]

Pages